# Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Study · id `cardio:ct-nct01476475` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01476475](<https://clinicaltrials.gov/study/NCT01476475>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01476475

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 323 participants.

## Technical summary

Registry record NCT01476475. Randomized; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2017-02-10.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 323 participants (enrolled count; ClinicalTrials.gov record NCT01476475, source copy `cardio:ctgov-nct01476475-2017-02-10`, retrieved 2026-10-26)
- Start date: 2011-11 (registry gives no type) (ClinicalTrials.gov record NCT01476475, source copy `cardio:ctgov-nct01476475-2017-02-10`, retrieved 2026-10-26)
- Primary completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01476475, source copy `cardio:ctgov-nct01476475-2017-02-10`, retrieved 2026-10-26)
- Completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01476475, source copy `cardio:ctgov-nct01476475-2017-02-10`, retrieved 2026-10-26)
- Results first posted: 2017-02-10 (ClinicalTrials.gov record NCT01476475, source copy `cardio:ctgov-nct01476475-2017-02-10`, retrieved 2026-10-26)
- Countries: United States; Chile; Czechia; Denmark; France; Germany; Hungary; Lithuania; Mexico; Poland; Romania; Slovakia; Sweden (ClinicalTrials.gov record NCT01476475, source copy `cardio:ctgov-nct01476475-2017-02-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01476475-2017-02-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine /lixisenatide Fixed Ratio Combination
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Metformin (Background drug)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial (`cardio:pubmed-27284114`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f056cd93ab03f798a6147cdca1a392c67f5d9cf466492845b7c17e26e2f8ad76
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
